Zentalis Pharmaceuticals Inc
NASDAQ:ZNTL
Zentalis Pharmaceuticals Inc
NASDAQ:ZNTL
Price:
2.71
USD
Market Closed
Market Cap:
$195.8m
Balance Sheet
Balance Sheet Decomposition
Zentalis Pharmaceuticals Inc
Zentalis Pharmaceuticals Inc
Balance Sheet Decomposition is not available for
Zentalis Pharmaceuticals Inc
Zentalis Pharmaceuticals Inc
Balance Sheet
Zentalis Pharmaceuticals Inc
Zentalis Pharmaceuticals Inc
Currency: USD
| Dec-2018 | Dec-2019 | Dec-2020 | Dec-2021 | Dec-2022 | Dec-2023 | Dec-2024 | ||
|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||
| Cash & Cash Equivalents |
25
|
67
|
55
|
60
|
43
|
28
|
34
|
|
| Cash Equivalents |
25
|
67
|
55
|
60
|
43
|
28
|
34
|
|
| Short-Term Investments |
0
|
0
|
284
|
280
|
394
|
455
|
337
|
|
| Total Receivables |
1
|
0
|
0
|
0
|
6
|
3
|
5
|
|
| Accounts Receivables |
1
|
0
|
0
|
0
|
0
|
0
|
5
|
|
| Other Receivables |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Current Assets |
1
|
2
|
6
|
11
|
8
|
14
|
10
|
|
| Total Current Assets |
27
|
69
|
345
|
351
|
452
|
497
|
386
|
|
| PP&E Net |
0
|
3
|
4
|
53
|
50
|
42
|
37
|
|
| PP&E Gross |
0
|
3
|
4
|
53
|
50
|
42
|
37
|
|
| Accumulated Depreciation |
0
|
0
|
0
|
1
|
2
|
3
|
4
|
|
| Intangible Assets |
9
|
9
|
9
|
0
|
0
|
0
|
0
|
|
| Goodwill |
4
|
4
|
4
|
4
|
4
|
4
|
0
|
|
| Long-Term Investments |
0
|
0
|
0
|
38
|
21
|
0
|
0
|
|
| Other Long-Term Assets |
2
|
3
|
4
|
10
|
12
|
9
|
7
|
|
| Other Assets |
4
|
4
|
4
|
4
|
4
|
4
|
0
|
|
| Total Assets |
41
N/A
|
88
+113%
|
366
+318%
|
455
+24%
|
539
+19%
|
552
+2%
|
430
-22%
|
|
| Liabilities | ||||||||
| Accounts Payable |
3
|
4
|
9
|
12
|
11
|
15
|
7
|
|
| Accrued Liabilities |
3
|
11
|
20
|
31
|
45
|
54
|
45
|
|
| Short-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Current Liabilities |
0
|
0
|
0
|
1
|
0
|
0
|
0
|
|
| Total Current Liabilities |
6
|
15
|
29
|
44
|
57
|
69
|
53
|
|
| Long-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Deferred Income Tax |
3
|
3
|
3
|
2
|
1
|
0
|
0
|
|
| Minority Interest |
8
|
7
|
25
|
1
|
0
|
0
|
0
|
|
| Other Liabilities |
0
|
2
|
1
|
45
|
48
|
45
|
40
|
|
| Total Liabilities |
16
N/A
|
26
+60%
|
57
+120%
|
91
+59%
|
106
+16%
|
114
+8%
|
93
-19%
|
|
| Equity | ||||||||
| Common Stock |
62
|
145
|
0
|
0
|
0
|
0
|
0
|
|
| Retained Earnings |
37
|
83
|
201
|
360
|
596
|
889
|
1 054
|
|
| Additional Paid In Capital |
0
|
0
|
509
|
724
|
1 032
|
1 324
|
1 391
|
|
| Unrealized Security Profit/Loss |
0
|
0
|
0
|
0
|
1
|
0
|
0
|
|
| Other Equity |
0
|
0
|
0
|
0
|
0
|
2
|
1
|
|
| Total Equity |
25
N/A
|
62
+148%
|
309
+401%
|
364
+18%
|
434
+19%
|
437
+1%
|
337
-23%
|
|
| Total Liabilities & Equity |
41
N/A
|
88
+113%
|
366
+318%
|
455
+24%
|
539
+19%
|
552
+2%
|
430
-22%
|
|
| Shares Outstanding | ||||||||
| Common Shares Outstanding |
35
|
35
|
41
|
46
|
59
|
71
|
71
|
|
Switch to:
Switch to:
See Also
Discover More
